Risk stratification in myelodysplastic syndromes: Is there a role for gene expression profiling?

Amer M. Zeidan, Thomas Prebet, Ehab Saad Aldin, Steven David Gore

Research output: Contribution to journalArticle

Abstract

Patients with myelodysplastic syndromes (MDS) exhibit wide heterogeneity in clinical outcomes making accurate risk-stratification an integral part of the risk-adaptive management paradigm. Current prognostic schemes for MDS rely on clinicopathological parameters. Despite the increasing knowledge of the genetic landscape of MDS and the prognostic impact of many newly discovered molecular aberrations, none to date has been incorporated formally into the major risk models. Efforts are ongoing to use data generated from genome-wide high-throughput techniques to improve the 'individualized' outcome prediction for patients. We here discuss an important paper in which gene expression profiling (GEP) technology was applied to marrow CD34+ cells from 125 MDS patients to generate and validate a standardized GEP-based prognostic signature.

Original languageEnglish (US)
Pages (from-to)191-194
Number of pages4
JournalExpert Review of Hematology
Volume7
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Gene Expression Profiling
Risk Management
Bone Marrow
Genome
Technology

Keywords

  • Gene expression profiling
  • international prognostic scoring system
  • myelodysplastic syndromes
  • prognostication
  • risk stratification

ASJC Scopus subject areas

  • Hematology

Cite this

Risk stratification in myelodysplastic syndromes : Is there a role for gene expression profiling? / Zeidan, Amer M.; Prebet, Thomas; Saad Aldin, Ehab; Gore, Steven David.

In: Expert Review of Hematology, Vol. 7, No. 2, 2014, p. 191-194.

Research output: Contribution to journalArticle

Zeidan, Amer M. ; Prebet, Thomas ; Saad Aldin, Ehab ; Gore, Steven David. / Risk stratification in myelodysplastic syndromes : Is there a role for gene expression profiling?. In: Expert Review of Hematology. 2014 ; Vol. 7, No. 2. pp. 191-194.
@article{737a7f9ba6a64277aac6eb34259fd10c,
title = "Risk stratification in myelodysplastic syndromes: Is there a role for gene expression profiling?",
abstract = "Patients with myelodysplastic syndromes (MDS) exhibit wide heterogeneity in clinical outcomes making accurate risk-stratification an integral part of the risk-adaptive management paradigm. Current prognostic schemes for MDS rely on clinicopathological parameters. Despite the increasing knowledge of the genetic landscape of MDS and the prognostic impact of many newly discovered molecular aberrations, none to date has been incorporated formally into the major risk models. Efforts are ongoing to use data generated from genome-wide high-throughput techniques to improve the 'individualized' outcome prediction for patients. We here discuss an important paper in which gene expression profiling (GEP) technology was applied to marrow CD34+ cells from 125 MDS patients to generate and validate a standardized GEP-based prognostic signature.",
keywords = "Gene expression profiling, international prognostic scoring system, myelodysplastic syndromes, prognostication, risk stratification",
author = "Zeidan, {Amer M.} and Thomas Prebet and {Saad Aldin}, Ehab and Gore, {Steven David}",
year = "2014",
doi = "10.1586/17474086.2014.891437",
language = "English (US)",
volume = "7",
pages = "191--194",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Risk stratification in myelodysplastic syndromes

T2 - Is there a role for gene expression profiling?

AU - Zeidan, Amer M.

AU - Prebet, Thomas

AU - Saad Aldin, Ehab

AU - Gore, Steven David

PY - 2014

Y1 - 2014

N2 - Patients with myelodysplastic syndromes (MDS) exhibit wide heterogeneity in clinical outcomes making accurate risk-stratification an integral part of the risk-adaptive management paradigm. Current prognostic schemes for MDS rely on clinicopathological parameters. Despite the increasing knowledge of the genetic landscape of MDS and the prognostic impact of many newly discovered molecular aberrations, none to date has been incorporated formally into the major risk models. Efforts are ongoing to use data generated from genome-wide high-throughput techniques to improve the 'individualized' outcome prediction for patients. We here discuss an important paper in which gene expression profiling (GEP) technology was applied to marrow CD34+ cells from 125 MDS patients to generate and validate a standardized GEP-based prognostic signature.

AB - Patients with myelodysplastic syndromes (MDS) exhibit wide heterogeneity in clinical outcomes making accurate risk-stratification an integral part of the risk-adaptive management paradigm. Current prognostic schemes for MDS rely on clinicopathological parameters. Despite the increasing knowledge of the genetic landscape of MDS and the prognostic impact of many newly discovered molecular aberrations, none to date has been incorporated formally into the major risk models. Efforts are ongoing to use data generated from genome-wide high-throughput techniques to improve the 'individualized' outcome prediction for patients. We here discuss an important paper in which gene expression profiling (GEP) technology was applied to marrow CD34+ cells from 125 MDS patients to generate and validate a standardized GEP-based prognostic signature.

KW - Gene expression profiling

KW - international prognostic scoring system

KW - myelodysplastic syndromes

KW - prognostication

KW - risk stratification

UR - http://www.scopus.com/inward/record.url?scp=84896334429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896334429&partnerID=8YFLogxK

U2 - 10.1586/17474086.2014.891437

DO - 10.1586/17474086.2014.891437

M3 - Article

C2 - 24559255

AN - SCOPUS:84896334429

VL - 7

SP - 191

EP - 194

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 2

ER -